Patents by Inventor Senta Voss

Senta Voss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab
    Patent number: 11058769
    Abstract: The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: July 13, 2021
    Assignees: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Gianluca Rinaldi, Alessandra Del Rio, Silvia Fratar-Cangeli, Senta Voss, Markus Weigandt
  • AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-L1 ANTIBODY AVELUMAB
    Publication number: 20210100903
    Abstract: The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.
    Type: Application
    Filed: December 9, 2020
    Publication date: April 8, 2021
    Inventors: Gianluca RINALDI, Alessandra DEL RIO, Silvia FRATAR-CANGELI, Senta VOSS, Markus WEIGANDT
  • Process for producing nanoparticles laden with active ingredient
    Patent number: 10561733
    Abstract: The present invention relates to a novel process for the production of nanoparticles laden with active compounds and to the use thereof as medicaments. The process for the production of nanoparticles comprises the steps (a) dissolution of at least one active compound and at least one polymer in an organic solvent, (b) mixing of the solution prepared in step (a) with an aqueous phase, (c) evaporation of the organic solvent, (d) purification of the nanoparticles laden with active compound obtained in step (c) by means of dialysis against aqueous dialysis solution comprising the same active compound.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: February 18, 2020
    Assignee: Merck Patent GmbH
    Inventors: Markus Weigandt, Senta Voss, Tobias Miller, Achim Goepferich
  • AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-L1 ANTIBODY AVELUMAB
    Publication number: 20180369377
    Abstract: The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.
    Type: Application
    Filed: December 5, 2016
    Publication date: December 27, 2018
    Applicants: MERCK PATENT GmbH, PFIZER INC.
    Inventors: Gianluca RINALDI, Alessandra DEL RIO, Silvia FRATAR-CANGELI, Senta VOSS, Markus WEIGANDT
  • PROCESS FOR PRODUCING NANOPARTICLES LADEN WITH ACTIVE INGREDIENT
    Publication number: 20150051181
    Abstract: The present invention relates to a novel process for the production of nanoparticles laden with active compounds and to the use thereof as medicaments. The process for the production of nanoparticles comprises the steps (a) dissolution of at least one active compound and at least one polymer in an organic solvent, (b) mixing of the solution prepared in step (a) with an aqueous phase, (c) evaporation of the organic solvent, (d) purification of the nanoparticles laden with active compound obtained in step (c) by means of dialysis against aqueous dialysis solution comprising the same active compound.
    Type: Application
    Filed: February 11, 2013
    Publication date: February 19, 2015
    Applicant: Merck Patent GmbH
    Inventors: Markus Weigandt, Senta Voss, Tobias Miller, Achim Goepferich